Democrats pressure Trump administration to rescue 10 other Americans detained in Russia

The Trump administration finalized a rule on Tuesday to cease gender-affirming care through Medicaid and the Children's Health Insurance Program (CHIP), a measure opponents claim will hinder vulnerable children's access to healthcare and endorse a transphobic ideology. The rule is set to commence on October 13, though legal challenges might delay or entirely nullify it.

The proposed rule garnered approximately 35,000 comments, with the vast majority opposing the change, according to Ma'ayan Anafi, senior counsel for health equity and justice at the National Women’s Law Center (NWLC). In their objection, the NWLC highlighted evidence supporting the safety and benefits of gender-affirming care. The NWLC described the rule as "incredibly dangerous" and cited the Cass Review in the UK, which they criticized for its biased evidence presentation, but they did not include the more recent, influential Dutch report affirming the safety and efficacy of gender-affirming care.

The administration's rule is driven by its anti-transgender agenda, Anafi asserted, stating that the policy reflects a "stigma" rather than following scientific evidence. This measure could also fuel similar restrictions at the state level. In December, HHS proposed another rule preventing health systems receiving Medicaid and Medicare payments from providing gender-affirming care, though there has been no further news on this proposal.

Simultaneously, HHS started using an obscure statute to refer health systems to prosecutors for offering gender-affirming care, leading to numerous major providers discontinuing such care. A federal judge blocked the administration from pursuing this prosecution in April, criticizing HHS Secretary Robert F. Kennedy Jr for disregarding the law and causing "very real harm to very real people."

If the new rule takes effect, states could utilize their portion of Medicaid funds not reimbursed by the US government to cover gender-affirming care, and individuals and organizations might increase mutual aid efforts. Gender-affirming care encompasses puberty blockers, hormones like estrogen and testosterone, surgery (though less common in children), and medical monitoring, such as bloodwork for tracking puberty and family support.

If the policy is enforced, children on Medicaid and CHIP would have six months to discontinue their medications. The administration has argued that gender-affirming care is costly without sufficient evidence of safety and clinical benefit, stating that federal healthcare dollars should support evidence-based care that prioritizes children's long-term health.

However, evidence-based, safe, and effective healthcare for transgender individuals, including youth, can yield life-saving advantages. Restrictions on such care can impede access and amount to an unofficial ban. The administration's focus on the cost of gender-affirming care reflects its broader stance on transgender healthcare.

Similar politically motivated restrictions have been observed for abortion care, indicating that such interference often results in patients struggling to access necessary care, with significant repercussions for their health and wellbeing. Medicaid and CHIP enrollees are less likely to have alternative funding sources for their care, and young Medicaid beneficiaries already face substantial healthcare barriers due to factors like poverty, race, and disability.

Anafi emphasized that this rule exacerbates existing barriers to care for those already facing significant obstacles. Granting political appointees the authority to dictate available medical care sets a troubling precedent for all types of healthcare, potentially weaponizing against various groups in the country. However, opposition to such policies is intensifying.

The NWLC reports that the backlash against this rule has been substantial, demonstrating the strength of resistance against misinformation and prejudice.